Anti-cytokine antibodies for rheumatic diseases

F. Atzeni, P. Sarzi-Puttini

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Improved knowledge regarding the pathogenetic mechanisms involved in autoimmune diseases has contributed to the development of biological therapies, with advances in cytokine research in particular revolutionizing the treatment of several autoimmune diseases. Anti-TNF agents are the most promising drugs for reducing symptoms, slowing or arresting joint damage, and preventing functional disability in patients with rheumatoid arthritis who fail to respond to standard disease-modifying antirheumatic drugs. Anti-TNF agents may also be useful in the treatment of other rare disorders, such as various forms of vasculitis, polymyositis and dermatomyositis. However, clinical trials of TNF inhibitors and inhibitors of the proinflammatory cytokines IL-1, IL-6, IL-12, IL-15, IL-17 and IL-23 demonstrated that the activity of such compounds is accompanied by a series of adverse events that needs to be addressed. This review describes the efficacy and adverse events associated with anti-cytokine treatments for autoimmune rheumatic diseases.

Original languageEnglish
Pages (from-to)1204-1211
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Volume10
Issue number11
Publication statusPublished - Nov 2009

Fingerprint

Rheumatic Diseases
Autoimmune Diseases
Anti-Idiotypic Antibodies
Cytokines
Interleukin-23
Interleukin-15
Biological Therapy
Antirheumatic Agents
Dermatomyositis
Interleukin-17
Interleukin-12
Vasculitis
Interleukin-1
Interleukin-6
Rheumatoid Arthritis
Therapeutics
Joints
Clinical Trials
Research
Pharmaceutical Preparations

Keywords

  • Anti-cytokine antibody
  • Autoimmune disease
  • MAb
  • Rheumatoid arthritis
  • TNF

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Atzeni, F., & Sarzi-Puttini, P. (2009). Anti-cytokine antibodies for rheumatic diseases. Current Opinion in Investigational Drugs, 10(11), 1204-1211.

Anti-cytokine antibodies for rheumatic diseases. / Atzeni, F.; Sarzi-Puttini, P.

In: Current Opinion in Investigational Drugs, Vol. 10, No. 11, 11.2009, p. 1204-1211.

Research output: Contribution to journalArticle

Atzeni, F & Sarzi-Puttini, P 2009, 'Anti-cytokine antibodies for rheumatic diseases', Current Opinion in Investigational Drugs, vol. 10, no. 11, pp. 1204-1211.
Atzeni, F. ; Sarzi-Puttini, P. / Anti-cytokine antibodies for rheumatic diseases. In: Current Opinion in Investigational Drugs. 2009 ; Vol. 10, No. 11. pp. 1204-1211.
@article{d6c7031e515a4444a0412111af74c062,
title = "Anti-cytokine antibodies for rheumatic diseases",
abstract = "Improved knowledge regarding the pathogenetic mechanisms involved in autoimmune diseases has contributed to the development of biological therapies, with advances in cytokine research in particular revolutionizing the treatment of several autoimmune diseases. Anti-TNF agents are the most promising drugs for reducing symptoms, slowing or arresting joint damage, and preventing functional disability in patients with rheumatoid arthritis who fail to respond to standard disease-modifying antirheumatic drugs. Anti-TNF agents may also be useful in the treatment of other rare disorders, such as various forms of vasculitis, polymyositis and dermatomyositis. However, clinical trials of TNF inhibitors and inhibitors of the proinflammatory cytokines IL-1, IL-6, IL-12, IL-15, IL-17 and IL-23 demonstrated that the activity of such compounds is accompanied by a series of adverse events that needs to be addressed. This review describes the efficacy and adverse events associated with anti-cytokine treatments for autoimmune rheumatic diseases.",
keywords = "Anti-cytokine antibody, Autoimmune disease, MAb, Rheumatoid arthritis, TNF",
author = "F. Atzeni and P. Sarzi-Puttini",
year = "2009",
month = "11",
language = "English",
volume = "10",
pages = "1204--1211",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "11",

}

TY - JOUR

T1 - Anti-cytokine antibodies for rheumatic diseases

AU - Atzeni, F.

AU - Sarzi-Puttini, P.

PY - 2009/11

Y1 - 2009/11

N2 - Improved knowledge regarding the pathogenetic mechanisms involved in autoimmune diseases has contributed to the development of biological therapies, with advances in cytokine research in particular revolutionizing the treatment of several autoimmune diseases. Anti-TNF agents are the most promising drugs for reducing symptoms, slowing or arresting joint damage, and preventing functional disability in patients with rheumatoid arthritis who fail to respond to standard disease-modifying antirheumatic drugs. Anti-TNF agents may also be useful in the treatment of other rare disorders, such as various forms of vasculitis, polymyositis and dermatomyositis. However, clinical trials of TNF inhibitors and inhibitors of the proinflammatory cytokines IL-1, IL-6, IL-12, IL-15, IL-17 and IL-23 demonstrated that the activity of such compounds is accompanied by a series of adverse events that needs to be addressed. This review describes the efficacy and adverse events associated with anti-cytokine treatments for autoimmune rheumatic diseases.

AB - Improved knowledge regarding the pathogenetic mechanisms involved in autoimmune diseases has contributed to the development of biological therapies, with advances in cytokine research in particular revolutionizing the treatment of several autoimmune diseases. Anti-TNF agents are the most promising drugs for reducing symptoms, slowing or arresting joint damage, and preventing functional disability in patients with rheumatoid arthritis who fail to respond to standard disease-modifying antirheumatic drugs. Anti-TNF agents may also be useful in the treatment of other rare disorders, such as various forms of vasculitis, polymyositis and dermatomyositis. However, clinical trials of TNF inhibitors and inhibitors of the proinflammatory cytokines IL-1, IL-6, IL-12, IL-15, IL-17 and IL-23 demonstrated that the activity of such compounds is accompanied by a series of adverse events that needs to be addressed. This review describes the efficacy and adverse events associated with anti-cytokine treatments for autoimmune rheumatic diseases.

KW - Anti-cytokine antibody

KW - Autoimmune disease

KW - MAb

KW - Rheumatoid arthritis

KW - TNF

UR - http://www.scopus.com/inward/record.url?scp=70449413372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449413372&partnerID=8YFLogxK

M3 - Article

C2 - 19876788

AN - SCOPUS:70449413372

VL - 10

SP - 1204

EP - 1211

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 11

ER -